Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus acidophilus DDS-1 + bifidobacterium lactis UABLA-12
- Development stage
- Unknown
- Lead developer
- Chr. Hansen
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A defined oral probiotic combination consisting of the live bacterial strains **Lactobacillus acidophilus DDS-1** and **Bifidobacterium lactis UABLA-12**. The combination has been developed and studied by groups associated with **UAS Laboratories** for gastrointestinal and immune-related conditions, including irritable bowel syndrome, atopic dermatitis, acute respiratory infections, and functional constipation. Its therapeutic rationale is microbiome modulation rather than receptor pharmacology: the live microbes are intended to alter gut microbial composition and metabolic activity, support intestinal barrier integrity, and modulate mucosal and systemic immune responses. In clinical studies, the combination has been administered orally at approximately **1 × 10^10 CFU/day per strain** or equivalent divided doses; in pediatric atopic dermatitis studies it has also been formulated with fructo-oligosaccharide as a synbiotic product. This is best characterized as a **probiotic nutraceutical/dietary supplement combination** rather than a conventional pharmaceutical drug.
- Other names
- Lactobacillus acidophilus DDS-1 + Bifidobacterium lactis UABLA-12L. acidophilus DDS-1 + B. lactis UABLA-12Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABLA-12
Beyond the preview
Go deeper on lactobacillus acidophilus DDS-1 + bifidobacterium lactis UABLA-12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus acidophilus DDS-1 + bifidobacterium lactis UABLA-12.